John C. Martin, the chief executive officer of Gilead Sciences Inc., has become a billionaire on the prospects of a powerful new hepatitis C drug that’s attracting scrutiny from payers and activists over its $1,000 per pill price tag.
Teva Pharmaceutical Industries Ltd. is using records from its 24-hour support hotline in the U.S. to persuade thousands of multiple sclerosis patients to switch from its biggest-selling drug, Copaxone, to a new version that has patent protection until 2030.
GlaxoSmithKline Plc Chief Financial Officer Simon Dingemans said the pharmaceutical industry should expect to see “many more” shifts over which drugs U.S. insurers cover than in the past, driven by pharmacy-benefits managers.
By ending the sale of tobacco products in its 7,600 pharmacies, CVS Caremark Corp. is redefining itself as a health-care provider in an environment in which millions of newly insured Americans will be looking for quick and convenient medical care.
GlaxoSmithKline Plc’s best-selling Advair drug for smokers’ cough and asthma is losing U.S. market share to products from AstraZeneca Plc and Merck & Co. after the country’s largest pharmacy-benefits manager dropped Advair from its 2014 list of reimbursed medicines.